Thomas, D and Farrell, M and McRobbie, H and Tutka, P and Petrie, D and West, R and Siahpush, M and Gartner, C and Walker, N and Mendelsohn, CP and Hall, W and Paul, C and Zwar, N and Ferguson, SG and Boland, VC and Richmond, R and Doran, CM and Shakeshaft, A and Mattick, RP and Courtney, RJ, The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial, Addiction, 114, (5) pp. 923-933. ISSN 0965-2140 (2019) [Refereed Article]
© 2018 Society for the Study of Addiction
Background and aims: Smoking cessation medications are effective, but often underutilized because of costs and side effects. Cytisine is a plant-based smoking cessation medication with more than 50 years of use in central and eastern Europe. While cytisine has been found to be well-tolerated and more effective than nicotine replacement therapy, direct comparisons with varenicline have not been conducted. This study evaluates the effectiveness, safety and costeffectiveness of cytisine compared with varenicline.
Design: Two-arm, parallel group, randomized, non-inferiority trial, with allocation concealment and blinded outcome assessment.
Setting: Australian population-based study.
Participants: Adult daily smokers (n = 1266) interested in quitting will be recruited through advertisements and Quitline telephone-based cessation support services. Intervention and comparator Eligible participants will be randomized (1 : 1 ratio) to receive either cytisine capsules (25-day supply) or varenicline tablets (12-week supply), prescribed in accordance with the manufacturer’s recommended dosing regimen. The medication will be mailed to each participant’s nominated residential address. All participants will also be offered standard Quitline behavioural support (up to six 10–12-minute sessions).
Measurements: Assessments will be undertaken by telephone at baseline, 4 and 7 months post-randomization. Participants will also be contacted twice (2 and 4 weeks post-randomization) to ascertain adverse events, treatment adherence and smoking status. The primary outcome will be self-reported 6-month continuous abstinence from smoking, verified by carbon monoxide at 7-month follow-up. We will also evaluate the relative safety and cost-effectiveness of cytisine compared with varenicline. Secondary outcomes will include self-reported continuous and 7-day point prevalence abstinence and cigarette consumption at each follow-up interview.
Comments: If cytisine is as effective as varenicline, its lower cost and natural plant-based composition may make it an acceptable and affordable smoking cessation medication that could save millions of lives world-wide.
|Item Type:||Refereed Article|
|Keywords:||cost-effectiveness, cytisine, randomized controlled trial, smoking cessation, tobacco, varenicline|
|Research Division:||Psychology and Cognitive Sciences|
|Research Field:||Biological Psychology (Neuropsychology, Psychopharmacology, Physiological Psychology)|
|Objective Division:||Expanding Knowledge|
|Objective Group:||Expanding Knowledge|
|Objective Field:||Expanding Knowledge in Psychology and Cognitive Sciences|
|UTAS Author:||Ferguson, SG (Associate Professor Stuart Ferguson)|
|Web of Science® Times Cited:||2|
Repository Staff Only: item control page